ArticlePharmacoEconomics2010
Principles of design of access with evidence development approaches: a consensus statement from the Banff Summit.
Article in PharmacoEconomics, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Mapping the landscape of managed entry agreements: a systematic review of global frameworks, system-level components, and implementation challenges.Frontiers in pharmacology · 2026Pooled it
- When does NICE recommend the use of health technologies within a programme of evidence development? : a systematic review of NICE guidance.PharmacoEconomics · 2013Pooled it
- Barriers and Opportunities for Implementation of Outcome-Based Spread Payments for High-Cost, One-Shot Curative Therapies.Frontiers in pharmacology · 2020Review
- Access to new cancer medicines in Australia: dispelling the myths and informing a public debate.Journal of pharmaceutical policy and practice · 2016Article
- Article
- Politics and its intersection with coverage with evidence development: a qualitative analysis from expert interviews.BMC health services research · 2013Article
- Role of centralized review processes for making reimbursement decisions on new health technologies in Europe.ClinicoEconomics and outcomes research : CEOR · 2011Article
- Access with evidence development: the US experience.PharmacoEconomics · 2010Article
- We know accurately only when we know little.PharmacoEconomics · 2010Article
- Single technology appraisal at the UK National Institute for Health and clinical excellence: a source of evidence and analysis for decision making internationally.PharmacoEconomics · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
20085388What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.